WS #11480
The dominant signal in this window is the OPEC+ decision to increase output quotas by 188,000 bpd from August, confirmed by multiple sources (OPEC statement, Reuters, Argus, investingLive). This is a continuation of the previously noted unwinding of cuts, but the new data point is the specific August increment. The narrative arc is STABLE: the increase is largely on paper due to ongoing Strait of Hormuz disruptions, and oil prices remain under pressure from IEA strategic releases and weak Chinese demand. TotalEnergies CEO comments that Gulf producers are heavily discounting crude to clear stockpiles, with the market needing 3-4 months to rebalance, adds a bearish supply signal. Iran's offer of special Hormuz fee terms to China introduces geopolitical uncertainty. A cargo ship attack in the Red Sea near Yemen, while not claimed, adds a risk premium to shipping routes. The NEJM retraction of a clinical trial underpinning Amgen's Tavneos approval is a high-significance negative for AMGN. The Supreme Court's Chatrie decision restricting geofence warrants is a negative for GOOGL's ad targeting. Stock futures are up (S&P +0.4%, Nasdaq +1.3%) on Sunday night, with the Dow near 53,000, but semiconductor weakness persists (SMH -3.2% last week). The RBNZ is expected to hike rates to 2.50% on July 8, a first in over three years. The easyJet-Castlelake takeover deal at £6.90/share is sector-specific. The Norway-Brazil World Cup result is non-market. The carry-forward from previous situational awareness is the OPEC+ quota increase, which remains a high-significance positive for energy bears (counters the supply disruption thesis).
Topics
Key developments
- OPEC+ agrees to raise output by 188,000 bpd from August, fifth consecutive increase
- TotalEnergies CEO: Gulf producers discounting crude to clear stockpiles, market needs 3-4 months to rebalance
- Iran offers special Hormuz fee terms to China, adding uncertainty to strait reopening
- Cargo ship attacked in Red Sea near Yemen, no claim of responsibility
- NEJM retracts clinical trial underpinning Amgen's Tavneos approval, putting drug sales at risk
- Supreme Court Chatrie decision restricts geofence warrants, impacting Google ad targeting
- RBNZ expected to hike rates 25bps to 2.50% on July 8, first hike in over three years
- Stock futures rise after record-setting week; Dow near 53,000, but semiconductor weakness persists